One fascinating area that Transcell is working on aims to replace the need for live animal testing in parts of the drug and vaccine development and manufacturing process.
“We believe Quantiphi’s passion for solving the most complex problems in life sciences including the creation of alternative methods to replace laboratory animal use in developing new drugs and products matches Transcell group’s vision of translating adult stem cell technology and its prowess to real-time applications. The partnership with Quantiphi will expedite medical research, population genetics, and drug development to achieve improved patient safety by leveraging Transcell’s biobanks’ ability to collect enormous amounts of human biological material coupled with its de-identified information,” said Dr. S. Dravida, Founder and CEO, Transcell.
“We wholeheartedly support and endorse this alliance to work together promoting discovery processes at reasonable costs and provide alternatives to human/animal drug and vaccine testing. Both the companies bring unique and complementary sets of skills and expertise into this relationship and I am sure we will produce high-value platform-based solutions for the global industry,” said Mr. Uday Chatterjee, Director, Transcell.
“The partnership with Transcell is an exciting opportunity to solve problems that matter. We hope to humanely replace live animal models with intelligent AI-based in-silico options that improve drug quality and testing at dramatically lower price points, which will improve the drug delivery models worldwide,” said Bruno Nardone, Global Head of Healthcare and Life Sciences at Quantiphi, “The strategic relationship with Transcell will bring the best of AI and stem cell technology together as next-generation methodologies to researchers, healthcare professionals, and ultimately patients through the creation of safe vaccines, therapeutics, and more.”
